Pharmacotherapy Impact on Cocaine and Alcohol-derived Reinforcement.

药物治疗对可卡因和酒精衍生强化的影响。

• 批准号: 8323963
• 负责人: Jennifer Grace Plebani
• 金额: $ 13万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8323963
• 关键词: Acute; Address; Adverse effects; Alcohols; Award; Behavioral; Chantix; Chronic; Clinical; Clinical Trials; Cocaine; Cocaine Dependence; Complement; Crossover Design; Data; Data Analyses; Dependence; Development; Doctor of Philosophy; Dose; Foundations; Funding; Future; Goals; Grant; Health Expenditures; Human; Human Volunteers; Hypertension; Individual; Instruction; Knowledge; Laboratories; Laboratory Study; Measurement; Mentors; Mentorship; Outpatients; Participant; Pennsylvania; Pharmaceutical Preparations; Pharmacotherapy; Physiological; Placebos; Postdoctoral Fellow; Principal Investigator; Psychological reinforcement; Public Health; Randomized; Relapse; Relative (related person); Research; Research Design; Research Personnel; Research Training; Safety; Secure; Self Administration; Societies; Socioeconomic Status; Structure; Substance Addiction; Testing; Training; Universities; addiction; base; behavioral pharmacology; cholinergic; cocaine use; cost; effective therapy; experience; human subject protection; huperzine A; interest; meetings; programs; randomized trial; varenicline

Cocaine use, abuse and dependence is a public health problem that Is directly responsible for hundreds of billions of dollars in health care expenditures per year. Relapse rates to cocaine use are high, creating a pressing need to develop effective therapies for cocaine dependence. As such, this research is important for furthering understanding of cocaine dependence, and for developing effective new treatments. The purpose of this application is to lay the foundation for Dr. Jennifer G. Plebani, Ph.D., a Postdoctoral Fellow at the University of Pennsylvania Center for Studies of Addiction (CSA), to become an independent investigator with expertise in pharmacotherapies for cocaine dependence, and a focus on human laboratory studies. The proposal builds on her existing knowledge of human behavioral laboratory studies for substance dependence, and limited clinical experience in substance dependence through a carefully structured training and research program involving didactic training, coursework, and experiential laboratory training. During the course of this award. Dr. Plebani will build on the postdoctoral mentorship she Is currently receiving from Dr. Helen Pettinati in treating cocaine dependence. She will be mentored by a team of investigators with experience in pharmacotherapies for cocaine (O'Brien and Kampman), human laboratory studies (Oslin), cocaine self-administration studies (Hart), studies of drug-derived reinforcement (Walsh), and statistical analysis and study design for within-subjects cross-over designs (Lynch). The proposed research and training will focus on investigating the determinants and consequences of cocaine dependence via measurement of physiological, behavioral and subjective effects of acute doses of cocaine in human volunteers in the laboratory, and through examination of the effects of pharmacotherapies on the above effects of cocaine. The two studies proposed will examine cocaine-derived reinforcement under week-long sub- chronic varenicline (Chantix") dosing, and under placebo conditions (Study 1), and under week-long sub-chronic Huperzine A dosing, and under placebo conditions (Study 2). Each study is a within- subjects crossover design. This KOI award will allow Dr. Plebani to establish the expertise required to secure ROI funding for future human behavioral pharmacology laboratory studies of cocaine dependence. RELEVANCE (See instructions): Cocaine use, abuse and dependence represent a public health problem that Is directly responsible for hundreds of billions of dollars in health care expenditures per year. As yet, no efficacious pharmacotherapies for cocaine dependence have been found. The goal of this project is to examine the potential efficacy of cholinergic medications in treating cocaine dependence.

可卡因的使用，滥用和依赖是一个直接负责的公共卫生问题 每年数千亿美元的医疗支出。可卡因使用的复发率是 高高，迫切需要开发有效的可卡因依赖疗法。因此，这个 研究对于进一步了解可卡因依赖性和发展有效 新治疗。本申请的目的是为Jennifer G. Plebani博士奠定基础 宾夕法尼亚大学成瘾研究中心（CSA）博士学位，博士学位 成为具有可卡因依赖性药物治疗专业知识的独立研究者， 并关注人类实验室研究。该提议建立在她现有的人类知识的基础上 实验室依赖性的行为实验室研究，物质的临床经验有限 通过涉及教学培训的精心结构化培训和研究计划的依赖， 课程和经验实验室培训。在本奖项期间。 Plebani博士将建造 她目前正在从海伦·佩蒂纳蒂（Helen Pettinati）博士接受可卡因的博士后指导上 依赖。她将受到具有药物治疗经验的调查员团队的指导 可卡因（O'Brien and Kampman），人类实验室研究（OSLIN），可卡因自我管理 研究（HART），药物衍生的增强研究（WALSH）以及统计分析和研究设计 用于主题内部设计（Lynch）。拟议的研究和培训将重点放在 通过测量可卡因依赖的决定因素和后果 可卡因急性剂量可卡因在人类志愿者中的生理，行为和主观作用 实验室，以及检查药物治疗对上述影响的影响 可卡因。提出的两项研究将检查在长达一周的亚第2次下的可卡因衍生的增强 慢性葡萄烯（Chantix”）给药，在安慰剂条件下（研究1），长达一周的时间 亚樱酸huperzine A剂量，在安慰剂条件下（研究2）。每项研究都是一个内部 受试者跨界设计。该锦护奖将使Plebani博士能够建立所需的专业知识 可卡因的未来人类行为药理学实验室研究的安全ROI资金 依赖。 相关性（请参阅说明）： 可卡因的使用，滥用和依赖代表了直接造成的公共卫生问题 每年数千亿美元的医疗支出。到目前为止，还没有有效的 发现可卡因依赖性的药物疗法。该项目的目的是检查 胆碱能药物在治疗可卡因依赖性方面的潜在功效。